AKT1 and diabetic retinopathy: Preclinical trials of rAAV‐based gene silencing aimed at the vascular endothelial growth factor (VEGF)/phosphatidylinositol 3‐kinase (PI3K)/protein kinase B, PKB (Akt) pathway in diabetic retinopathy (DR) have shown promising results in decreasing the permeability of retinal blood vessels in DR rats.20